Therapeutic Thursday: GSK Bets Big, And Europe's Pricing Problem Gets A Face
An ADC with ambitions across five tumor types. A £1.9bn cost cut to fund a pipeline push. And a breast cancer drug caught between a stalled FDA review and a European pricing standoff.